Impurity profiling is of significant analytical and regulatory importance, particularly in the context of lifecycle quality management. A robust chaotropic chromatography method was developed for the determination of olanzapine and its two oxidative degradation products in tablets, in accordance with the ICH Q14 guideline and the principles of Analytical Quality by Design (AQbD). Risk assessment was performed using a combination of the Ishikawa diagram, CNX (Control, Noise and eXperimental) classification, and Failure Mode and Effect Analysis (FMEA). This multistep evaluation identified the critical analytical procedure parameters (APPs) as the acetonitrile content in the mobile phase, the concentration of perchloric acid in the aqueous phase, and the pH of the aqueous phase. These APPs were studied using an experimental design approach to model their effects on key analytical procedure attributes and to compute a multidimensional design space. Robust optimization supported by Monte Carlo simulations ensured compliance with predefined acceptance criteria with a probability of at least 95%. Method validation demonstrated adequate selectivity, limits of quantification of 0.75 µg/mL and 0.5 µg/mL for impurities B and D, linearity with correlation coefficients ≥0.990, accuracy of 98–102% for olanzapine and 70–130% for impurities, and repeatability with RSD ≤2% for the assay and ≤10% for impurities. The method was successfully applied to commercial tablet analysis.
Rmandić et al. (Thu,) studied this question.